secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046085
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD
--------------------------------------------------------------------------------

- Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).
- Cash $20.0M at Dec 31, 2024; expected to fund operations into Q4 2025.
- FDA alignment on Phase 3 for CLS-AX in wet AMD: two non-inferiority trials, sham control, after positive Phase 2b.
- Partner Arctic Vision NDA for ARCATUS (XIPERE) in uveitic macular edema accepted in China; also approved in Australia and Singapore.
- Tony Gibney appointed Chair of Board effective November 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/0000950170-25-046085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025046085/clsd-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer